Disposable Autoinjectors Market - 2025-2033

Disposable Autoinjectors Market Size

Disposable Autoinjectors Market Size reached US$ 712.30 Million in 2024 and is expected to reach US$ 3,073.24 Million by 2033, growing at a CAGR of 17.8% during the forecast period 2025-2033.

The demand for the disposable autoinjector market is experiencing significant growth. For instance, according to the National Institute of Health (NIH), more than 20 pharmaceutical companies have developed nearly 80 autoinjectors. Nearly 50 drugs are developed as combination products for administration using autoinjectors. Among these, 62% of the autoinjectors are disposable. The market demand for disposable autoinjectors has been steadily increasing due to several key factors, including the growing prevalence of chronic diseases, advancements in drug formulations, and the push towards self-administration.

Disposable Autoinjectors Market Dynamics: Drivers & Restraints

The rising prevalence of chronic diseases is significantly driving the disposable autoinjectors market growth

With the global rise in diabetes, the demand for insulin delivery systems like autoinjectors has increased. For instance, according to the International Diabetes Federation (IDF), by 2050, IDF projections show that 1 in 8 adults, approximately 853 million, will be living with diabetes, an increase of 46%. The rising number of diabetes patients is driving demand for autoinjectors for insulin administration as autoinjectors offer a convenient and safer method for patients to administer insulin at home, which is crucial for managing the condition.

The growing use of biologics and monoclonal antibodies for treating autoimmune diseases and cancer has spurred demand for autoinjectors. These drugs require precise dosing and reliable administration, which autoinjectors provide. The introduction of devices like the Humira Pen for rheumatoid arthritis and other autoimmune diseases exemplifies the market’s response to biologics, showing an increased demand for patient-friendly, self-administration devices.

The increasing prevalence of various chronic diseases such as diabetes, rheumatoid arthritis, multiple sclerosis, and others is a notable shift towards self-administration due to its convenience and the ability to manage conditions discreetly. Disposable autoinjectors cater to this trend by allowing patients to administer their medications at home without the need for healthcare provider intervention.

For instance, in January 2024, Taisho Pharmaceutical Co., Ltd. announced that the Nanozora 30 mg Disposable Autoinjector for S.C. Injection (generic name: ozoralizumab, (recombinant)), a TNFα inhibitor is launched. The drug employs a device that considers ease of use for patients with rheumatoid arthritis (RA). Taisho aims to provide new treatment options for patients with RA, offering Nanozora 30mg Syringes for S.C. Injection and Nanozora 30mg Autoinjector for S.C. Injection.

Availability of alternative drug delivery systems is hampering the disposable autoinjectors market

The availability of alternative drug delivery systems, which include traditional syringe injections, inhalers, and other forms of drug delivery, can offer competitive advantages such as cost-effectiveness, ease of use, and different treatment experiences.

Traditional syringes remain a cost-effective option for drug delivery, especially in low-resource settings. They are widely available and familiar to both healthcare providers and patients, making them an attractive alternative to disposable autoinjectors. For instance, in some regions, the cost of using disposable autoinjectors can be significantly higher compared to conventional syringes, which can deter adoption. In healthcare systems where budgets are limited, the preference for traditional syringes can slow the uptake of autoinjectors.

Generic and low-cost alternatives to branded epinephrine autoinjectors, like Auvi-Q, have gained traction. These alternatives offer similar efficacy at a lower price point, making them more accessible to a broader patient population. This competition can reduce the market share of branded disposable autoinjectors, as cost-conscious consumers opt for more affordable options.

Disposable Autoinjectors Market Segment Analysis

The global disposable autoinjectors market is segmented based on type, application, end-user, and region.

The prefilled autoinjectors from the product type segment are expected to hold 61.55% of the market share in 2024 in the disposable autoinjectors market

Prefilled autoinjectors are designed for ease of use, allowing patients to self-administer medications without the need for healthcare provider assistance. These devices typically come pre-filled with the medication, eliminating the need for patients to fill the device themselves. The design of prefilled autoinjectors, such as those used for insulin delivery and other medications, simplifies the administration process and reduces the potential for user error. Major market players are developing the prefilled autoinjectors, which further boosting the segment growth.

For instance, in January 2024, Taisho Pharmaceutical Co., Ltd. launched the Nanozora 30 mg Autoinjector for S.C. Injection (generic name: ozoralizumab, (recombinant)), a TNFα inhibitor. Nanozora 30mg Autoinjector for S.C. Injection is a single-use autoinjector dosage form, prefilled with the same drug as the syringe dosage form, Nanozora 30mg Syringe for S.C. Injection. Users can easily inject the drug simply by pressing the injector against the skin. The needle cover will be locked after injection to prevent needle-piercing accidents.

Disposable Autoinjectors Market Geographical Analysis

North America is expected to dominate the global disposable autoinjectors market with a 43.17% share in 2024

North America, particularly the United States, boasts a highly developed healthcare infrastructure, which includes advanced hospitals, research facilities, and specialized clinics. This infrastructure supports the adoption of advanced drug delivery technologies such as disposable auto-injectors. For instance, major healthcare providers and facilities across the U.S. utilize auto-injectors for treating conditions like rheumatoid arthritis and multiple sclerosis, which are common in the region. This widespread usage creates a strong demand for disposable autoinjectors.

In the U.S., self-administration of medications using auto-injectors has been widely adopted for chronic disease management. For example, therapies for rheumatoid arthritis and multiple sclerosis are commonly delivered via auto-injectors like the Sensoready and Rebif, respectively. The convenience and safety of these devices make them highly preferred among patients, contributing to the dominance of North America in this market.

Asia-Pacific is growing at the fastest pace in the disposable autoinjectors market, holding 22.34% of the market share

Countries in the APAC region, particularly Japan, China, and India, are witnessing substantial increases in healthcare spending as governments allocate more resources towards improving healthcare infrastructure. For instance, China’s National Healthcare Security Administration has been expanding insurance coverage to include more advanced medical devices like auto-injectors. This expansion boosts the adoption of these devices across the region.

There is growing awareness among patients in the APAC region regarding the benefits of self-administered therapies. This awareness is being driven by healthcare campaigns, education programs, and the increased availability of auto-injectors through pharmacies and healthcare facilities. For instance, countries like India are seeing increased awareness about the benefits of using prefilled auto-injectors for treating conditions like rheumatoid arthritis.

Disposable Autoinjectors Market Top Companies

Top companies in the disposable autoinjectors market include Becton, Dickinson, and Company, Ypsomed AG, Owen Mumford Inc., Phillips Medisize, SHL Medical, Stevanato Group, Faxne, and Dali Medical Devices, among others.

Key Developments

• In April 2025, argenx SE, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, announced that the U.S. Food and Drug Administration (FDA) approved a new option for patients to self-inject VYVGART Hytrulo with a prefilled syringe (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor (AChR) antibody positive and adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

• In January 2025, UCB, a global biopharmaceutical company, announced that a single-injection 2 mL prefilled syringe and autoinjector, each containing 320 mg of BIMZELX (bimekizumab-bkzx), is now available. These are in addition to the currently available 1 mL device administration options, each containing 160 mg of BIMZELX.

• In November 2024, Amneal Pharmaceuticals, Inc. resubmitted to the U.S. Food and Drug Administration (FDA) its new drug application (NDA) for dihydroergotamine (DHE) prefilled syringe autoinjector for the acute treatment of migraine with or without aura and cluster headache in adults.

The global disposable autoinjectors market report delivers a detailed analysis with 56 key tables, more than 52 visually impactful figures, and 147 pages of expert insights, providing a complete view of the market landscape.